Evidence map›Paper›PMID 38183506›Full record

ArticleMolecular biology reports2024

The urolithin B nanomicellar delivery system as an efficient selective anticancer compound.

Noor Oudah Mohammed Albuthyab, Hossein Hosseini, Masoud Homayouni Tabrizi, Matin Kharaghani, Seyedeh Samira Saghravanian

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.9field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Noor Oudah Mohammed AlbuthyabDepartment of Biology, Science and Research branch, Islamic Azad University, Tehran, Iran.
Hossein HosseiniDepartment of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. hoseinihs@mums.ac.ir.
Masoud Homayouni TabriziDepartment of Biology, Mashhad Branch, Islamic Azad University, Mashhad, Iran.
Matin KharaghaniDepartment of Biology, Mashhad Branch, Islamic Azad University, Mashhad, Iran.
Seyedeh Samira SaghravanianDepartment of Biology, Mashhad Branch, Islamic Azad University, Mashhad, Iran.
Islamic Azad University, Mashhad · IRIslamic Azad University, Science and Research Branch · IRMashhad University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundUrolithin B (UB), the antioxidant polyphenol has a protective impact on several organs against oxidative stress. However, its bioactivity is limited by its hydrophobic structure. In the current study, UB was encapsulated into a liposomal structure to improve its bioactivities anticancer, and antimicrobial potential.

methodThe UB nano-emulsions (UB-NE) were synthesized and characterized utilizing FESEM, DLS, FTIR, and Zeta-potential analysis. The UB-NMs' selective toxicity was studied by conducting an MTT assay on MCF-7, PANC, AGS, and ASPC1 cells. The AO/PI analysis verified the UB-NMs' cytotoxicity on ASPC1 cell lines and approved the MTT results. Finally, the antibacterial activity of the UB-NMs was studied on both gram-positive (B. subtilis, S. aureus) and gram-negative (E. Coli, P. aeruginosa) bacteria by conducting MIC and MBC analysis.

resultThe 68.15 nm UB-NMs did not reduce the normal HDF cells' survival. However, they reduced the cancer cells' (PANC and AGS cell lines) survival at high treatment concentrations (> 250 µg/mL) compared with normal HDF and cancer MCF-7 cells. Moreover, the IC

conclusionThe significant selective cytotoxic impact of the UB-NMs on the human pancreatic tumor cell line makes it an applicable anti-pancreatic cancer compound. Moreover, the antibacterial activity of UB-NMs has the potential to decrease bacterial-mediated pancreatic cancer. However, several bacterial strains and further cancer cell lines are required to verify the UB-NMs' anticancer potential.

Indexed as

Escherichia coliPancreatic NeoplasmsAnti-Bacterial AgentsCoumarinsHumansMCF-7 CellsStaphylococcus aureusAnti-Bacterial AgentsCoumarinsurolithin BAnti-bactericidal activityBacterial-mediated Pancreatic cancerSelective cytotoxicityUB nano-emulsions (UB-NMs)

Identifiers

PMID38183506
OpenAlexW4390635751

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.